Global Fund: U.K. Multilateral Aid Review & Support; Mali program suspension

The Global Fund noted that it was one of 9 international organizations determined to have an “excellent track record” for delivering results and would receive increased funding in the future, based on the U.K. Multilateral Aid Review (MAR). The review “found that the Global Fund played a critical role in delivering health-related Millennium Development Goals (MDGs) and was likely to remain a key financier of existing and new approaches to tackling AIDS, tuberculosis and malaria.” The purpose of the Multilateral Aid Review, commissioned by the UK’s Department for International Development (DFID), was “to assess whether the UK is getting the best possible value for the money that it contributes to international organizations.” The review also gave the Global Fund “high marks for transparency and accountability, saying that the ‘Fund’s decision to publish/require recipients to publish procurement data has been a major driver for a range of innovations in transparency.’”

Separately, the Global Fund announced suspension of a US$13.91 million HIV/AIDS grant to Mali “with immediate effect until new arrangements for managing the grant are in place to safeguard Global Fund assets. The current Principal Recipient, Groupe Pivot Santé Population, will be replaced. The decision to suspend the grant comes after evidence was discovered that Global Fund grant money has been misused. It is part of a process of restoring confidence in the ability of Mali’s health sector to manage Global Fund resources appropriately.” In December 2010, the Global Fund suspended funding of two malaria grants in Mali and terminated a third grant for tuberculosis “after evidence of misappropriation and unjustified expenditure was found. The suspended grant provides funding for prevention programs, including condom distribution, voluntary counseling and testing and support for children who have been orphaned or made vulnerable by the AIDS epidemic. The grant suspension does not affect any of the 22,500 patients on antiretroviral treatment in Mali. They are financed by a second grant, managed by the National High Council for HIV/AIDS control of Mali, which is not affected by this decision.”